



Investor service announcement no. 6/2014

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, 31 October, 2014

Veloxis Pharmaceuticals A/S to Host Conference Call discussing the FDA tentative approval of Envarsus® XR

Veloxis Pharmaceuticals A/S (OMX: VELO) Veloxis' Management will host a conference call to discuss the FDA tentative approval of Envarsus® XR on Tuesday 4 November, 2014 at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM EST (New York),

To access the live conference call, please dial one of the following numbers:

+45 32 72 80 18 (Denmark)

+44 (0) 1452 555 131 (UK)

+1 866 682 8490 (USA)

For more information, please contact:

Veloxis Pharmaceuticals A/S

William J. Polvino

President & CEO

Tel: +1 732 321 3202

Email: wjp@veloxis.com

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.